Amgen Inc. (AMGN) Stock Analysis
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest independent biotechnology companies, discovering and manufacturing human therapeutics across oncology, cardiovascular, inflammation, bone health, and hematology. Investors research AMGN for its established product portfolio, dividend yield, and exposure to aging-population healthcare trends.
Get a full AI research report on AMGN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes biologic drugs globally, generating revenue primarily from blockbuster medications including Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), and KYPROLIS (multiple myeloma). The company operates a capital-intensive R&D model, investing heavily in pipeline development while monetizing a mature, diversified product portfolio with strong pricing power in developed markets. Revenue is derived from both established therapies and newer launches like TEPEZZA (thyroid eye disease) and EVENITY (osteoporosis).
Bull case
- ✓Gross margin of 71.9% reflects strong pricing power and manufacturing efficiency typical of established biotech firms with proprietary therapies.
- ✓Forward P/E of 17.3 is notably lower than the trailing P/E of 26.4, suggesting market expectations for earnings growth in coming years.
- ✓Operating margin of 35.5% and net margin of 23.0% demonstrate substantial profitability and cash generation capacity relative to revenue.
- ✓Dividend yield of 2.4% with a 61% payout ratio provides income while retaining capital for R&D and shareholder returns.
- ✓Diversified therapeutic portfolio across multiple disease areas and geographies reduces dependence on any single product or market.
Bear case
- ✗Debt-to-equity ratio of 490% indicates substantial leverage, raising questions about financial flexibility and refinancing risk in rising rate environments.
- ✗Trailing P/E of 26.4 remains elevated relative to historical biotech averages, potentially limiting upside if growth expectations reset.
- ✗PEG ratio of 2.58 suggests the stock may be priced above growth rates, warranting scrutiny of pipeline success and near-term revenue drivers.
- ✗Return on equity of 91.5% is exceptionally high, which may reflect accounting effects or capital structure rather than sustainable operational performance.
- ✗Biosimilar competition and patent expirations on key products pose ongoing revenue headwinds that require successful new product launches to offset.
AMGN valuation & financial health
Amgen trades at a trailing P/E of 26.4 with a forward P/E of 17.3, indicating the market is pricing in earnings expansion. The company's profitability metrics are robust: gross margin of 71.9%, operating margin of 35.5%, and net margin of 23.0% reflect the high-margin nature of biologic therapeutics. However, the debt-to-equity ratio of 490% is notably elevated, suggesting the balance sheet is heavily leveraged—a consideration for investors evaluating financial stability. The current ratio of 1.37 and quick ratio of 0.95 indicate adequate short-term liquidity, though the quick ratio below 1.0 warrants monitoring. Return on assets of 8.7% is modest relative to the high ROE, underscoring the impact of financial leverage on shareholder returns.
The bottom line
Amgen presents a classic mature biotech profile: established profitability, strong cash generation, and a diversified product portfolio offset by significant leverage and valuation that assumes continued earnings growth. The forward P/E discount to trailing P/E suggests the market expects near-term expansion, but this depends on pipeline execution and management of patent cliff risks. Investors should weigh the company's dividend income and market-leading position against leverage levels, competitive biosimilar pressures, and whether current valuations fairly reflect long-term growth prospects. Monitoring upcoming clinical trial results, new product adoption, and debt management strategy will be critical to assessing risk-reward.
Frequently asked questions
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and distributes biologic drugs for conditions including rheumatoid arthritis, cardiovascular disease, osteoporosis, cancer, and blood disorders. The company operates globally and generates revenue from both established blockbuster therapies and newer product launches.
Is AMGN overvalued?
Amgen's trailing P/E of 26.4 is elevated relative to historical biotech averages, though the forward P/E of 17.3 reflects market expectations for earnings growth. Whether this represents fair value depends on pipeline success, patent cliff management, and long-term revenue visibility—factors investors should evaluate individually.
Does Amgen pay a dividend?
Yes, Amgen pays a dividend with a yield of 2.4% and a payout ratio of 61%, meaning the company returns a meaningful portion of earnings to shareholders while retaining capital for R&D and debt service.
What are Amgen's main products?
Key products include Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), KYPROLIS (multiple myeloma), TEPEZZA (thyroid eye disease), and Otezla (psoriasis and psoriatic arthritis), among others.
What is Amgen's debt situation?
Amgen has a debt-to-equity ratio of 490%, indicating substantial leverage. While the company generates strong cash flow to service debt, this high leverage limits financial flexibility and warrants monitoring in changing interest rate environments.
What risks should I monitor with AMGN?
Key risks include biosimilar competition eroding revenues on established products, patent expirations, pipeline execution risk, high leverage, and valuation sensitivity to earnings growth assumptions. Regulatory changes and pricing pressure in key markets also merit attention.
Research AMGN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.